Moors & Cabot
VRTX icon

Moors & Cabot’s Vertex Pharmaceuticals VRTX Stock Holding History

Moors & Cabot’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.94M Buy
3,704
+314
+9% +$161K 0.07% 244
2026
Q2 		$1.68M Sell
3,390
-166
-5% -$73.6K 0.07% 267
2026
Q1 		$1.59M Buy
3,556
+77
+2% +$35.9K 0.07% 258
2025
Q4 		$1.58M Sell
3,479
-100
-3% -$43.1K 0.07% 255
2025
Q3 		$1.4M Sell
3,579
-555
-13% -$232K 0.06% 281
2025
Q2 		$1.84M Sell
4,134
-1,363
-25% -$628K 0.09% 218
2025
Q1 		$2.67M Buy
5,497
+1,894
+53% +$883K 0.14% 147
2024
Q4 		$1.45M Buy
3,603
+25
+0.7% +$11.6K 0.07% 250
2024
Q3 		$1.66M Sell
3,578
-161
-4% -$77.3K 0.08% 219
2024
Q2 		$1.75M Sell
3,739
-201
-5% -$87.2K 0.09% 192
2024
Q1 		$1.65M Buy
3,940
+47
+1% +$19.9K 0.09% 214
2023
Q4 		$1.58M Sell
3,893
-422
-10% -$156K 0.1% 196
2023
Q3 		$1.5M Sell
4,315
-189
-4% -$66.1K 0.1% 195
2023
Q2 		$1.59M Buy
4,504
+412
+10% +$139K 0.11% 192
2023
Q1 		$1.29M Sell
4,092
-194
-5% -$58.2K 0.09% 229
2022
Q4 		$1.24M Buy
4,286
+198
+5% +$60.3K 0.09% 234
2022
Q3 		$1.18M Buy
4,088
+23
+0.6% +$6.62K 0.09% 230
2022
Q2 		$1.14M Buy
4,065
+182
+5% +$48.7K 0.08% 238
2022
Q1 		$1.01M Buy
3,883
+701
+22% +$166K 0.06% 289
2021
Q4 		$699K Buy
+3,182
New +$619K 0.04% 375
2021
Q1 		– Sell
-1,642
Closed -$387K – 839
2020
Q4 		$387K Sell
1,642
-164
-9% -$37.6K 0.03% 449
2020
Q3 		$491K Sell
1,806
-219
-11% -$60.4K 0.05% 332
2020
Q2 		$591K Buy
2,025
+47
+2% +$12.7K 0.06% 278
2020
Q1 		$474K Sell
1,978
-286
-13% -$65.6K 0.07% 258
2019
Q4 		$496K Buy
+2,264
New +$458K 0.05% 345

Other funds holding VRTX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $194B AUM 32.2% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Moors & Cabot's VRTX Position: Q3 2026 in Review

Moors & Cabot increased its Vertex Pharmaceuticals (VRTX) stake by 9.3% in Q3 2026, buying an estimated $161K and bringing the position to 3,704 shares worth $1.94M. The position accounts for 0.07% of the portfolio, ranked #244.

Moors & Cabot first reported a position in VRTX in Q4 2019 and has held it in 25 quarters since. The position peaked at $2.67M in Q1 2025. 992 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Moors & Cabot held 3,704 shares of Vertex Pharmaceuticals worth $1.94M as of Q3 2026.
  • Moors & Cabot bought 314 Vertex Pharmaceuticals shares in Q3 2026, an estimated $161K.
  • Vertex Pharmaceuticals made up 0.07% of Moors & Cabot's portfolio in Q3 2026, its #244 holding.
  • Moors & Cabot first reported a position in Vertex Pharmaceuticals in Q4 2019 and has held it in 25 quarters since.
  • Moors & Cabot's Vertex Pharmaceuticals position peaked at $2.67M in Q1 2025.
  • 992 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Moors & Cabot's 13F filing for Q3 2026, filed 6 Nov 2026.